Shilpa Medicare has entered into a long-term development and commercial manufacturing agreement with Switzerland-based NXI Therapeutics AG to support the advancement of innovative immunomodulatory therapies.

Under the agreement, Shilpa Medicare will provide end-to-end Chemistry, Manufacturing and Controls (CMC) development, process scale-up, GMP clinical supply and commercial manufacturing support for NXI Therapeutics’ programme. The collaboration is expected to span the full product lifecycle, from early-stage development through to commercialisation, positioning Shilpa as a strategic lifecycle partner for the programme.

The partnership comes amid growing global demand for autoimmune and immune-modulation therapies, one of the fastest-expanding therapeutic segments driven by rising disease prevalence and increasing focus on targeted immunotherapies. By securing the mandate at an early stage, Shilpa aims to strengthen its participation in high-value, innovation-led pharmaceutical pipelines with long-term commercial scalability.

The agreement marks the third named partnership announced by the Raichur-based pharmaceutical company in the past year, reflecting the rapid expansion of its Contract Development and Manufacturing Organisation (CDMO) business as Western biotech firms increasingly seek integrated R&D and advanced GMP manufacturing capabilities.

Although financial details of the deal have not been disclosed, the agreement reportedly includes milestone-linked expansion opportunities and may evolve into a multi-year commercial supply arrangement, subject to successful clinical and regulatory progress.

Vishnukanth Bhutada, Managing Director of Shilpa Medicare, said the collaboration reinforces the company’s transition into a strategic innovation partner for global biotech companies. He added that Shilpa’s integrated development and commercial manufacturing capabilities position it to support complex therapeutic assets across the entire product lifecycle while strengthening growth visibility for its CDMO platform.

Dr. Ruben Herrendorff, CEO of NXI Therapeutics AG, said Shilpa’s scientific expertise, quality systems and scalable GMP manufacturing infrastructure made it a suitable partner for advancing the company’s immunomodulatory programme toward future clinical and commercial milestones.

With continued investments in biologics capabilities, advanced GMP facilities and global biotech collaborations, Shilpa Medicare is further strengthening its position as a trusted development and manufacturing partner in high-growth therapeutic categories.